Cleavage of mitochondrial antiviral signaling protein in the liver of patients with chronic hepatitis C correlates with a reduced activation of the endogenous interferon system.

Division of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland.
Hepatology (Impact Factor: 11.19). 04/2010; 51(4):1127-36. DOI: 10.1002/hep.23426
Source: PubMed

ABSTRACT Hepatitis C virus (HCV) infection induces the endogenous interferon (IFN) system in the liver in some but not all patients with chronic hepatitis C (CHC). Patients with a pre-activated IFN system are less likely to respond to the current standard therapy with pegylated IFN-alpha. Mitochondrial antiviral signaling protein (MAVS) is an important adaptor molecule in a signal transduction pathway that senses viral infections and transcriptionally activates IFN-beta. The HCV NS3-4A protease can cleave and thereby inactivate MAVS in vitro, and, therefore, might be crucial in determining the activation status of the IFN system in the liver of infected patients. We analyzed liver biopsies from 129 patients with CHC to investigate whether MAVS is cleaved in vivo and whether cleavage prevents the induction of the endogenous IFN system. Cleavage of MAVS was detected in 62 of the 129 samples (48%) and was more extensive in patients with a high HCV viral load. MAVS was cleaved by all HCV genotypes (GTs), but more efficiently by GTs 2 and 3 than by GTs 1 and 4. The IFN-induced Janus kinase (Jak)-signal transducer and activator of transcription protein (STAT) pathway was less frequently activated in patients with cleaved MAVS, and there was a significant inverse correlation between cleavage of MAVS and the expression level of the IFN-stimulated genes IFI44L, Viperin, IFI27, USP18, and STAT1. We conclude that the pre-activation status of the endogenous IFN system in the liver of patients with CHC is in part regulated by cleavage of MAVS.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Vitamin D is an important secosteroid hormone with known effect on calcium homeostasis, but recently there is increasing recognition that vitamin D also is involved in cell proliferation and differentiation, has immunomodulatory and anti-inflammatory properties. Vitamin D deficiency has been frequently reported in many causes of chronic liver disease and has been associated with the development and evolution of non-alcoholic fatty liver disease (NAFLD) and chronic hepatitis C (CHC) virus infection. The role of vitamin D in the pathogenesis of NAFLD and CHC is not completely known, but it seems that the involvement of vitamin D in the activation and regulation of both innate and adaptive immune systems and its antiproliferative effect may explain its importance in these liver diseases. Published studies provide evidence for routine screening for hypovitaminosis D in patients with liver disease. Further prospectives studies demonstrating the impact of vitamin D replacement in NAFLD and CHC are required.
    World journal of hepatology. 12/2014; 6(12):901-15.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The clinical exploitation of type I interferon (IFN) as an antiviral and antineoplastic agent is based on the original properties attributed to this cytokine family, with schedules and modalities that reflect their antiviral and antiproliferative activities. Nevertheless, type I IFN has emerged as a central activator of the innate immunity, with the capacity to induce potent immune responses against foreign pathological agents. Physiologically, type I IFN is produced in large amounts by plasmacytoid dendritic cells and is rapidly silenced by self-regulatory mechanisms. The current schedule of treatment for infectious diseases, especially chronic hepatitis C, as well as for a limited number of hematological and solid tumors is based on the continuous administration of either intermediate or high dose recombinant or pegylated type I IFN, regardless of emerging data on the viral resistance, host genetic variants predicting treatment outcome and multiple mechanisms of refractoriness. New administration schedules, the combination of type I IFN with new drugs and increased monitoring of patients’ susceptibility are expected to provide a new life to this valuable cytokine.
    Cytokine & Growth Factor Reviews 12/2014; · 6.54 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Despite the development of potent antiviral drugs, HCV remains a global health problem; global eradication is a long way off. In this review, we discuss the immune response to HCV infection and particularly, the interplay between viral strategies that delay the onset of antiviral responses and host strategies that limit or even eradicate infected cells but also contribute to pathogenesis. Although HCV can disable some cellular virus-sensing machinery, IFN-stimulated antiviral genes are induced in the infected liver. Whereas epitope evolution contributes to escape from T cell-mediated immunity, chronic high antigen load may also blunt the T cell response by activating exhaustion or tolerance mechanisms. The evasive maneuvers of HCV limit sterilizing humoral immunity through rapid evolution of decoy epitopes, epitope masking, stimulation of interfering antibodies, lipid shielding, and cell-to-cell spread. Whereas the majority of HCV infections progress to chronic hepatitis with persistent viremia, at least 20% of patients spontaneously clear the infection. Most of these are protected from reinfection, suggesting that protective immunity to HCV exists and that a prophylactic vaccine may be an achievable goal. It is therefore important that we understand the correlates of protective immunity and mechanisms of viral persistence.
    Journal of Leukocyte Biology 07/2014; · 4.30 Impact Factor

Full-text (2 Sources)

Available from
Sep 13, 2014